128 related articles for article (PubMed ID: 38237003)
1. Establishment of Anti-Dog Programmed Cell Death Ligand 1 Monoclonal Antibodies for Immunohistochemistry.
Ouchida T; Suzuki H; Tanaka T; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2024 Feb; 43(1):17-23. PubMed ID: 38237003
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal Antibody L
Yamada S; Itai S; Nakamura T; Yanaka M; Chang YW; Suzuki H; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2018 Apr; 37(2):110-115. PubMed ID: 29608408
[TBL] [Abstract][Full Text] [Related]
3. Development and characterization of mouse anti-canine PD-L1 monoclonal antibodies and their expression in canine tumors by immunohistochemistry
Sirivisoot S; Boonkrai C; Wongtangprasert T; Phakham T; Muanwein P; Pisitkun T; Sawangmake C; Radtanakatikanon A; Rungsipipat A
Vet Q; 2023 Dec; 43(1):1-9. PubMed ID: 37477617
[TBL] [Abstract][Full Text] [Related]
4. Anti-PD-L1 therapy altered inflammation but not survival in a lethal murine hepatitis virus-1 pneumonia model.
Curran CS; Cui X; Li Y; Jeakle M; Sun J; Demirkale CY; Minkove S; Hoffmann V; Dhamapurkar R; Chumbris S; Bolyard C; Iheanacho A; Eichacker PQ; Torabi-Parizi P
Front Immunol; 2023; 14():1308358. PubMed ID: 38259435
[TBL] [Abstract][Full Text] [Related]
5. Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L
Yamada S; Itai S; Kaneko MK; Kato Y
Biochem Biophys Rep; 2018 Mar; 13():123-128. PubMed ID: 29556567
[TBL] [Abstract][Full Text] [Related]
6. A defucosylated anti-PD-L1 monoclonal antibody 13-mG
Takei J; Ohishi T; Kaneko MK; Harada H; Kawada M; Kato Y
Biochem Biophys Rep; 2020 Dec; 24():100801. PubMed ID: 32923698
[TBL] [Abstract][Full Text] [Related]
7. Cross-reactivity of anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody, clone 28-8 against feline PD-L1.
Nishibori S; Sakurai M; Kagawa Y; Uchida K; Nakagawa T; Igase M; Mizuno T
J Vet Med Sci; 2023 Jun; 85(6):592-600. PubMed ID: 37150603
[TBL] [Abstract][Full Text] [Related]
8. Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry.
Takei J; Asano T; Nanamiya R; Nakamura T; Yanaka M; Hosono H; Tanaka T; Sano M; Kaneko MK; Harada H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):71-75. PubMed ID: 33900817
[TBL] [Abstract][Full Text] [Related]
9. Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function.
Choi JW; Withers SS; Chang H; Spanier JA; De La Trinidad VL; Panesar H; Fife BT; Sciammas R; Sparger EE; Moore PF; Kent MS; Rebhun RB; McSorley SJ
PLoS One; 2020; 15(7):e0235518. PubMed ID: 32614928
[TBL] [Abstract][Full Text] [Related]
10. Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans.
Oh W; Kim AMJ; Dhawan D; Kirkham PM; Ostafe R; Franco J; Aryal UK; Carnahan RH; Patsekin V; Robinson JP; Knapp DW; Lim SO
Cancer Res Commun; 2023 May; 3(5):860-873. PubMed ID: 37377896
[TBL] [Abstract][Full Text] [Related]
11. A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints.
Li Y; Li F; Jiang F; Lv X; Zhang R; Lu A; Zhang G
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27438833
[TBL] [Abstract][Full Text] [Related]
12. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
13. [The Mechanism of PD-L1 Expression and the Development of Biomarker of Anti-PD-1/Anti-PD-L1 Monoclonal Antibody from the Viewpoint of IFN-γ].
Nakayama Y; Mimura K; Kono K
Gan To Kagaku Ryoho; 2019 May; 46(5):838-840. PubMed ID: 31189799
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors.
Maekawa N; Konnai S; Asano Y; Otsuka T; Aoki E; Takeuchi H; Kato Y; Kaneko MK; Yamada S; Kagawa Y; Nishimura M; Takagi S; Deguchi T; Ohta H; Nakagawa T; Suzuki Y; Okagawa T; Murata S; Ohashi K
PLoS One; 2023; 18(1):e0281143. PubMed ID: 36701405
[TBL] [Abstract][Full Text] [Related]
15. A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx).
Guo L; Overholser J; Darby H; Ede NJ; Kaumaya PTP
Oncoimmunology; 2022; 11(1):2127691. PubMed ID: 36211807
[TBL] [Abstract][Full Text] [Related]
16. mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1).
Kamalinia G; Engel BJ; Srinivasamani A; Grindel BJ; Ong JN; Curran MA; Takahashi TT; Millward SW; Roberts RW
ACS Chem Biol; 2020 Jun; 15(6):1630-1641. PubMed ID: 32352272
[TBL] [Abstract][Full Text] [Related]
17. In Vivo Imaging of the Programmed Death Ligand 1 by
González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL
J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151
[TBL] [Abstract][Full Text] [Related]
18. An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1.
Cogswell J; Inzunza HD; Wu Q; Feder JN; Mintier G; Novotny J; Cardona DM
Mol Diagn Ther; 2017 Feb; 21(1):85-93. PubMed ID: 27667773
[TBL] [Abstract][Full Text] [Related]
19. Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models.
Kurino T; Matsuda R; Terui A; Suzuki H; Kokubo T; Uehara T; Arano Y; Hisaka A; Hatakeyama H
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32041818
[TBL] [Abstract][Full Text] [Related]
20. Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1.
Nemoto Y; Shosu K; Okuda M; Noguchi S; Mizuno T
Vet Immunol Immunopathol; 2018 Apr; 198():19-25. PubMed ID: 29571514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
